US Patent Issued to Mission Therapeutics on July 14 for "N-cyanopyrrolidines with activity as USP30 inhibitors" (British Inventors)

ALEXANDRIA, Va., July 14 -- United States Patent no. 12,679,833, issued on July 14, was assigned to Mission Therapeutics Ltd. (Cambridge, Great Britain).

"N-cyanopyrrolidines with activity as USP30 inhibitors" was invented by Christopher Andrew Luckhurst (Cambridge, Great Britain), Mark Ian Kemp (Cambridge, Great Britain) and Paul William Thompson (Cambridge, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: (formulae (I)(i) and (I)(ii))."

Th...